"10.1371_journal.pone.0083575","plos one","2014-01-17T00:00:00Z","Valentina Di Caro; Brett Phillips; Carl Engman; Jo Harnaha; Massimo Trucco; Nick Giannoukakis","Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America; RiMed Foundation, Palermo, Italy; Penn State University Hershey Medical Center, Hershey, Pennsylvania, United States of America; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America","Conceived and designed the experiments: NG VD BP MT. Performed the experiments: VD BP CE JH. Analyzed the data: NG VD BP CE JH MT. Wrote the paper: NG BP MT.","The authors have read the journal′s policy and have the following conflicts. Nick Giannoukakis and Massimo Trucco are on the Scientific Advisory Board and hold equity in the form of common stock of DIAVACS, a biotechnology entity that has licensed the following intellectual property pertaining to iDC from the University of Pittsburgh (patents relating to the dendritic cells referred to in the manuscript). The authors have the following patent(s) relating to material pertinent to this article (A Microsphere-based composition for preventing and/or reversing new-onset autoimmune disease; US 8,022,046; A Method for reversing diabetes/decreasing inflammation of pancreas; US 7,964,574 and US 8,389,493; Compositions of microspheres targeting co-stimulation; US 7,884,085; Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same; US 6,936,468). There are no further patents, products in development or marketed products to declare. This does not alter the authors′ adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Valentina Di Caro","VDC",6,TRUE,4,4,6,3,TRUE,TRUE,FALSE,0,NA,FALSE
